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six assessments that resulted in conditional reimbursement were targeted therapies. 
Typically, with these targeted therapies, PFS or OS ranged from ~3 months to 9 
months with the cost-per-QALY > £45.000. Five of the six manufactures participated 
in a patient-access scheme which consisted of ﬁ xed-price discounts such as Cetuximab 
(CRC) and Geﬁ tinib (NSCLC) or performance schemes like sunitinib (GIST), Bortezo-
mib (myeloma), and Lenalidome (myeloma). CONCLUSIONS: Based on the retro-
spective analysis, it is clear that the biggest challenge for targeted-cancer therapies is 
affordability with only one of the targeted therapies receiving unconditional reim-
bursement. However, nearly all the other targeted therapies evaluated that offered >3 
months OS or PFS were recommended by NICE with a proviso to bring down the 
cost of treatment. Therefore, when companies develop their market access strategy, 
they should include a patient-access scheme in order to enter the UK market.
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OBJECTIVES: Achieving market access for new products has become complex for 
pharmaceutical companies. Faced with growing expenditure, health-care authorities 
accept or propose various schemes (risk sharing/payment for performance/commer-
cial): UK’s Department of Health coined a term Patient Access Scheme (PAS) and 
published speciﬁ c guidance for the industry. We performed an in-depth analysis of 
design of PASs in UK to revisit their typology and rationale. METHODS: We reviewed 
ofﬁ cial and grey literature on the Web sites of UK’s HTA Agency—NICE, the Depart-
ment of Health (DoH), the industry, and in the Internet. We searched for documents 
containing all synonimes of PAS and different scheme types. We selected PASs 
launched after 2006. RESULTS: We identiﬁ ed 13 PASs, all of which were designed/
implemented in consultation with NICE. Drug’s comparative effectiveness was central 
to the rationale behind the design of PASs. If effectiveness was acknowledged in the 
HTA, PAS was based on cost-containment (rituximab, erlotinib). If it was not recog-
nized, this was for one of the two reasons: (1) the uncertainity about the long-term 
effect of the drug, or (2) the value of ICER was questioned in the HTA. In case of 
(1), the PAS consisted in free provision of the drug by manufacturer after a predeﬁ ned 
period (lenalidomide, ranibizumab). In the case of (2), the PAS aimed at lowering the 
ICER either through cost containment (sunitinib, cetuximab, pemetrexed), through 
linking payment to outcomes (bortezomib, omalizumab), or by a mix of the two 
(certolizumab, ustekinumab). CONCLUSIONS: Formalized Health Technology 
Assessment is both a prerequisite and reason for implementing Patient Access Schemes 
in the UK. If the comparative effectiveness of a drug is acknowledged, the agreement 
is based on cost containment. On the other hand, if it is questioned, the PAS may 
have a form of a risk-sharing scheme and may be linking the payment to health 
outcomes (performance-based scheme).
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OBJECTIVES: Since its establishment, NICE has become increasingly explicit about 
the way it uses evidence on cost-effectiveness in decision-making—and, more recently, 
about the other factors it considers. This, together with other ways in which decision-
making has evolved, suggests a number of testable hypotheses. We propose and 
empirically test alternative ways that NICE decision-making might be modeled, build-
ing on and extending Devlin and Parkin (2004) and Dakin et al. (2006). The large 
number of NICE decisions now observable facilitates the use of more sophisticated 
modeling techniques. METHODS: NICE’s decisions are characterized as binary 
choices: yes or no to a technology in a speciﬁ cally deﬁ ned patient group or indication. 
NICE Guidance often contains multiple such decisions. The probability of NICE 
recommending a technology is modeled as depending on evidence on effectiveness and 
cost-effectiveness; characteristics of the patients, disease, or treatment; and contextual 
factors. Data were obtained from HTAinSite (http://www.htainsite.com) on November 
2009. RESULTS: Initial results, drawing on data for 262 decisions, suggest cost-
effectiveness alone explains the vast majority of NICE’s decisions, correctly classifying 
85%, with high sensitivity and speciﬁ city. The estimated threshold, around £40k, is 
higher than NICE’s stated threshold (20k–£30k) but similar to that estimated by 
Devlin and Parkin (2004). Results across alternative model speciﬁ cations showed that 
almost none of the other variables exert a statistically signiﬁ cant effect on decisions, 
with two exceptions. First, technologies for the treatment of cancer have a signiﬁ cantly 
higher probability of being accepted, ceteris paribus, implying a willingness to pay an 
additional >£10k per QALY gained by cancer patients. Second, analysis of the subset 
of decisions made after NICE’s second “social value judgement” document suggest an 
increased probability of rejection. CONCLUSIONS: This is work in progress; further 
results will be available to report from additional data extraction and modeling.
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OBJECTIVES: In the UK, Patient Access Schemes (PAS) have become more common 
in submissions to the National Institute for Health and Clinical Excellence (NICE). 
The increase in PAS is a result of the essential role such schemes play in enhancing 
the availability of high-cost treatments to payers. In published appraisals, minimal 
emphasis has been placed upon the administrative burden of PAS, which is typically 
described as “acceptable.” The aim of this study was to assess the impact of admin-
istering PAS in the UK, using both primary research and existing literature to identify 
key administrative challenges. METHODS: A literature search was conducted using 
PubMed and Google Scholar. Freedom of information requests were sent to NICE for 
data on PAS administration. a pilot questionnaire was distributed to all 19 contacts 
listed on the directory of NHS Chief Pharmacists in Wales, to assess the real-life 
burden of PAS administration. RESULTS: Limited literature is available on the admin-
istration of PAS. However, the literature search uncovered evidence that the admin-
istrative impact of PAS is being recognized. The creation of the Patient Access Scheme 
Liaison Unit (PASLU) in October 2009 and the publication of the Pharmaceutical 
Price Regulation Scheme (PPRS) are two such developments, both of which are steps 
toward a system that more accurately reﬂ ects the needs of NHS administrators. The 
return rate for the questionnaire was low; however, responders showed dissatisfaction 
with multiple aspects of PAS management. Responders emphasized the need to address 
NHS requirements (both ﬁ nancial and temporal) in order to facilitate accurate PAS 
administration. CONCLUSIONS: Encouraging steps have been taken to recognize the 
burden of PAS on the NHS; however, further research is required to assess whether 
these recent developments are meaningful in everyday practice. Additional support for 
appropriate PAS implementation must also be provided if these important schemes are 
to continue effectively. 
PODIUM SESSION III: BIASES, METHODOLOGICAL CHALLENGES, AND 
SOLUTIONS
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BACKGROUND: Offering patients in oncology trials the opportunity to cross over 
to active treatment at disease progression is a commonly used strategy to address 
ethical issues associated with the use of placebo controls, but could lead to statistical 
challenges for the analysis of key end points such as overall survival. While an advan-
tage from the perspective of the treated patient enrolled in the trial, cross-over leads 
to loss of information and dilution of the comparative clinical efﬁ cacy and cost-
effectiveness results. OBJECTIVES: The purpose of the study is to compare alternative 
methods for analyzing overall survival data in the presence of cross-over, thus illustrat-
ing differences between methods, and providing guidance on choice of methodology. 
METHODS: Two promising methods for dealing with cross-over are inverse probabil-
ity of censoring weighting and the rank-preserving structural failure time model. The 
methods are compared with naïve censoring of data at cross-over and intention-to-
treat analysis ignoring cross-over using two recent examples of trials in oncology: the 
receptor tyrosine kinase inhibitor sunitinib in renal cell carcinoma (RCC) and in 
gastrointestinal stromal tumor (GIST). RESULTS: The analyses showed that for a trial 
with a low proportion of cross-over from placebo to active treatment (RCC), the 
choice of statistical method did not affect the results to a great extent; the range of 
relative mortality risk for active treatment versus control was narrow. With a high 
proportion of cross-over (GIST), the range of relative mortality risks was broader. 
CONCLUSIONS: Naïve censoring at cross-over can lead to bias and should be 
avoided. If cross-over occurs frequently, the inverse probability of censoring weighting 
method or the rank-preserving structural failure time model are recommended depend-
ing on the characteristics of cross over in the trial, trial size, and available data.
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BACKGROUND: Models are widely used in the cost-effectiveness analysis of health-
care interventions. Most models only simulate one patient cohort, but some use 
multiple cohorts. Advocates of multicohort modeling contend it better represents 
actual health-care implementation, especially where interventions are applied over 
speciﬁ c age ranges, as in cancer screening. When such an intervention is introduced, 
cohorts already older than the starting age only receive a partial intervention, possibly 
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resulting in cost-effectiveness different to that of younger cohorts that receive the 
complete intervention: multi-cohort models can include both these “complete” and 
“partial” cohorts. Some multi-cohort models described as population models impose 
ﬁ nite time horizons at which the intervention is assumed to cease, although health 
effects are typically assessed until death. ANALYSIS: If cost-effectiveness differs 
between partial and complete cohorts, then the overall cost-effectiveness estimate from 
a multi-cohort model will depend on the relative numbers of partial and complete 
cohorts. The total number of complete cohorts depends on how long the intervention 
is used, which is uncertain. Therefore, the overall estimate may depend, in part, on 
the number of future cohorts assumed. The appropriateness of time horizons depends 
on whether a cross-sectional or a longitudinal cohort approach is used. Assuming an 
intervention ceases at a time horizon is unrepresentative of actual implementation and 
may result in biased cost-effectiveness estimates for curtailed cohorts. CONCLUSION: 
Multi-cohort modeling is advocated as being more representative of actual implemen-
tation. However, a single cost-effectiveness estimate for multiple cohorts necessarily 
implies an aggregation of estimates. Such aggregation leaves estimates sensitive to 
assumptions of the number of cohorts included, can hide useful information, and lead 
to nonoptimal policy choices. We suggest cost-effectiveness estimates for the complete 
and incomplete cohorts should not be aggregated, but reported separately. Implemen-
tation time horizons should not be used in longitudinal cohort-based modeling in 
cost-effectiveness analysis.
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BACKGROUND: Cost-effectiveness models are often used to predict the costs and 
health outcomes that are likely to be associated with various different interventions. 
Models are a useful tool for representing the detailed and complex “real world” in a 
more simple and understandable structure. While models do not claim to necessarily 
create an exact replica of the real world, they can be useful in demonstrating the 
relationships and interactions between various different factors. However, developers 
of models often consciously, and unconsciously, make assumptions that are avoidable 
and may bias the results of a model. METHODS: A review was undertaken on a 
random selection of published models in different disease areas to aim to identify the 
frequency of typical “errors” in economic models. In addition, a simple model was 
developed and used to explore the relative impact of different types of errors in models. 
Each type of error was examined for its likely impact on the model’s overall ﬁ ndings 
and conclusions. This helped to gain a greater understanding of both the frequency 
of different errors and their magnitude of effect. RESULTS: Mistakes are commonly 
observed in economic models. These were often due to limitations in scope of the 
model, but all were found to be avoidable given unlimited time and data availability. 
As well as identifying “major” errors in models, the review also identiﬁ ed many 
common errors, such as excluding “half cycle correction,” that often have very little 
impact on a model’s results, relative to other common errors. CONCLUSIONS: While 
many errors in economic models are frequent, many errors often go unnoticed and 
have signiﬁ cant impact upon a model’s results. This analysis has highlighted the rela-
tive importance of each type of error and has provided suggestions as to how these 
might be avoided.
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OBJECTIVES: Discrepancies in diagnosis, treatment, or prognosis may emerge among 
physicians. a known decision-making bias is the tendency to shift personal opinion 
either toward or away from a previous opinion. We sought to evaluate such biases in 
the context of second-opinion medical consultations. METHODS: We distributed a 
survey questionnaire to a nationwide sample of orthopedic surgeons and neurologists. 
The questionnaires presented eight scenarios, each with conventional treatment 
options with no clear-cut preference. In four scenarios, the physicians were told that 
a previous opinion had already been given by another physician, or that a second 
opinion will be given, and the other four scenarios were used as controls. The physi-
cians’ responses were coded according to the level of intervention (conservative to 
interventional). RESULTS: 172 orthopedic surgeons and 160 neurologists ﬁ lled out 
the questionnaires, which represent about 50% of these specialties in Israel. In the 
orthopedic questionnaire, when a ﬁ rst opinion had already been given, there was a 
shift toward a more interventionist treatment (P < 0.05). This was especially prominent 
when the ﬁ rst opinion was known to the second physician. When the patient intended 
to seek a second opinion, there was a shift toward a more conservative treatment. No 
such effect was found among neurologists. CONCLUSIONS: Physicians’ judgment 
may be affected by another physician’s opinion (compared to their choices without a 
ﬁ rst opinion). This bias mainly tends toward a more interventionist treatment. Due 
to the immense impact of any decision on patient health and resource use, further 
research should address such biases and develop tools to address them. 
PODIUM SESSION III: HTA POLICY APPROACHES
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OBJECTIVES: Regulators and payers view randomized controlled trials (RCT) as the 
gold standard for establishing the beneﬁ t/risk of new drugs. However, they are increas-
ingly interested in real-world data (RWD) due to their external validity. This survey 
explored stakeholders’ perceptions and emerging trends in the area of RWD. 
METHODS: We identiﬁ ed relevant literature since 2006 via Google Scholar and 
manual search, and reviewed it based on several topics: types of RWD, pros and cons 
of different approaches, and impact of new statistical techniques and technology on 
availability and quality of RWD. We then conducted 45–60 min in-depth, semistruc-
tured discussions with 17 experts from Academia, HTA bodies, health insurance, 
research organizations, and pharmaceutical industry—from the UK, France, Germany, 
the The Netherlands, and the United States. Their views about value and future direc-
tions of RWD approaches were elicited. RESULTS: Experts unanimously thought that 
RCTs would remain a mandatory approach for the foreseeable future due to the limi-
tations of RWD, mainly potential for confounding. New study designs (e.g., random-
ized database studies) and statistical techniques (e.g., high-dimensional propensity 
scoring) remove confounding only partially and need to gain credibility. There was a 
strong view that, while registries have been the reference source of observational data, 
there is an opportunity for (claims) database and electronic medical records to form 
an efﬁ cient platform for automatic, real-time analysis of naturalistic data. Despite a 
few good examples, it will, however, require time to resolve technical difﬁ culty of 
linking databases and, crucially, the challenges of data ownership and privacy issues. 
Several experts predict the short-term rise of at-home monitors, “smart pills,” and 
“smart phones” that automatically feed into databases, and the increased use of data 
from Google Health and Microsoft HealthVault. CONCLUSIONS: RWD may eventu-
ally become the new gold standard in drug development, but this will occur only 
through incremental progress.
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OBJECTIVES: Prices of recently launched targeted therapies are relatively high and 
patient access differs between European countries. Advanced renal cell cancer (aRCC) 
is a rare malignancy with poor prognosis for which four such drugs are available: 
sunitinib, sorafenib, bevacizumab, and temsirolimus. We investigated relations 
between funding decisions of national health authorities and patient access to these 
treatments. METHODS: We reviewed Web sites of health authorities in France, 
Germany, Italy, and UK. Data on drug utilization from June 2006 to July 2009 were 
extracted from the Synovate Oncology Monitor, an ongoing prescription database 
based on doctors’ diaries. Total sample size varied between countries, from 7766 to 
9463 patients within the year ending 2009 Q2. RESULTS: Sunitinib was granted 
restricted recommendation by NICE (UK) in March 2009, but other treatments were 
not assessed during study period. All drugs were ﬁ nanced through payment-for-per-
formance schemes (P4PS) with a registry in Italy. In France, bevacizumab and temsi-
rolimus were reimbursed on top of DRGs and in Germany only bevacizumab. 
Sunitinib was the ﬁ rst line treatment in 62%, 50%, 47%, and 31% of drug-treated 
patients in France 2006Q3–2009Q2), Germany, Italy, and UK, respectively, followed 
by temsirolimus in France and Germany but sorafenib in Italy. Sorafenib was the most 
widely used second line treatment in Germany and Italy. In France, temsirolimus was 
used off-label in ﬁ rst line and bevacizumab before funding decision in aRCC was 
granted. In UK, many patients remained untreated. CONCLUSIONS: Funding on top 
of DRGs in France contributed to early uptake and off-label usage. P4PS were associ-
ated with enhanced drug uptake in Italy. In UK, the lack of assessment by NICE 
prevented patient access, which raises concern about the current ﬁ nancing system. The 
large differences in patient access to recently approved cancer treatments raise the 
issue of equity and health outcomes associated with innovative drugs.
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OBJECTIVES: Payer expectations for reimbursement from novel drugs are constantly 
increasing. Understanding these is crucial during evidence generation. Expectations in 
terms of clinical outcomes vary across EU countries. This study compared payer 
awareness and expectations in two disease areas with contrasting prevalence and 
subsequent impact on health-care budgets, and thus their impact on reimbursement. 
METHODS: The study was conducted in EU5 markets. Opinions of 36 stakeholders 
were collected via telephone interviews. Value drivers for new drugs were tested 
including unmet need, clinical data—safety and efﬁ cacy, cost-effectiveness, budget 
